tiprankstipranks
Trending News
More News >

Oryzon Genomics Secures €13.26 Million for VANDAM Project under IPCEI

Story Highlights
Oryzon Genomics Secures €13.26 Million for VANDAM Project under IPCEI

Confident Investing Starts Here:

The latest announcement is out from Oryzon Genomics SA ( (ES:ORY) ).

Oryzon Genomics S.A. has been granted a non-refundable aid of approximately €13.26 million from the Med4Cure project, the first Important Project of Common European Interest (IPCEI) in the healthcare sector. This funding will support the VANDAM project, covering 64% of its total budget, and will enable Oryzon to accelerate the clinical development of its epigenetic agents, vafidemstat and iadademstat, for treating rare diseases and hard-to-treat cancers, thereby strengthening its financial position and enhancing its mental health program.

More about Oryzon Genomics SA

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company and a European leader in epigenetics. The company focuses on developing personalized medicine approaches for rare and orphan diseases, particularly in the field of central nervous system disorders and neuroendocrine cancers.

Average Trading Volume: 1,428,253

Technical Sentiment Signal: Buy

Current Market Cap: €202.3M

Learn more about ORY stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App